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The serum glycoprotein fetuin-A is an important inhibitor of
extra-osseous calcification, but correlations between serum
fetuin-A levels and the extent of vascular calcification are
controversial. In this study, we used a rat model of adenine-
induced renal failure with secondary hyperparathyroidism
that exhibits all characteristic features of patients with
chronic kidney disease. These rats had medial vascular
calcification along with reduced levels of both serum and
hepatic fetuin-A. Treatment with an inhibitor of ectopic
calcification, alendronate, decreased bone turnover and
eliminated completely the vascular calcification in this rat
model, but there was no change in the levels of hepatic and
serum fetuin-A. Centrifugation of the serum of untreated rats
with renal failure gave a small precipitate composed of
fetuin-A, calcium, magnesium, and phosphate; this complex,
absent from normal rat serum, was not found in the serum of
alendronate-treated rats with renal failure. Rat serum
contained three types of phosphorylated fetuin-A, as well as
unphosphorylated forms, but only the fully phosphorylated
fetuin-A was present in the mineral complex. The amount of
this complex reflected the risk of mineral precipitation. Our
results suggest that the measurement of serum
fetuin–mineral complex rather than fetuin-A alone might
provide a better indication of extra-osseous calcification
propensity.
Kidney International (2009) 75, 915–928; doi:10.1038/ki.2008.700;
published online 4 February 2009
KEYWORDS: fetuin-A; fetuin–mineral complex; extra-osseous calcification
stress; renal failure
Vascular calcification is common in aging, diabetes, and
chronic kidney disease (CKD) and is associated with
increased cardiovascular morbidity and mortality.1–3 There
are two readily distinguishable histoanatomic vascular
calcification variants: medial artery calcification and athero-
sclerotic intimal calcification.4,5 As Moe et al. have observed,
it is the medial vascular calcification that is predominant in
CKD patients. As medial artery calcification portends the
high mortality of CKD patients independently of intimal
calcification,6 it is important to evaluate accurately the risk
status for medial calcification.
As the physiological serum concentrations of calcium and
phosphate are several orders of magnitude above their
solubility products, mechanisms inhibiting precipitation
must be operative in order to prevent extra-osseous
calcification. Several molecules have been revealed to
participate in this mechanism, including matrix Gla protein,
osteoprotegerin, and fetuin-A.7,8 Among these, reverse acute
phase protein fetuin-A is a good candidate extra-osseous
calcification inhibitor, particularly in CKD patients. Abun-
dant serum glycoprotein fetuin-A is synthesized in liver,
secreted into blood, and thereby exerts potent inhibition of
calcification.9 After the report from Ketteler et al., which
showed clearly the relationship between all-cause/cardiovas-
cular mortality and low serum fetuin-A levels in hemodialysis
patients, substantial attention has been focused on this
molecule.10 Moe et al. verified the negative correlation
between coronary artery calcification scores and serum
fetuin-A levels in patients with CKD stage 5.11 In addition
to several clinical studies on CKD patients,12,13 low serum
fetuin-A has been revealed to be associated with carotid
arterial stiffness, independent of known atherogenic factors
in healthy individuals.14
Despite this accumulated evidence, we have been unable
to identify any significant relationship between serum fetuin-
A concentrations and coronary artery calcification scores in
diabetic pre-dialysis CKD patients.15 In addition to our
study, Hermans et al. and Jung et al. also reported that serum
fetuin-A is not an independent predictor of aortic stiffness
and coronary artery calcification scores in dialysis
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patients.16,17 Moreover, Mehrotra et al. reported that there is
a positive relationship between serum fetuin-A levels and
coronary artery calcification scores, in non-dialyzed patients
with diabetic nephropathy.18
Here, we examined the characteristics of fetuin-A under
extra-osseous calcification stress. We selected adenine-
induced renal failure rats in this study, as this model
produces renal failure, secondary hyperparathyroidism, and
medial calcification, which resembles the characteristics of
human CKD patients.19–21 The aim of this study was to
evaluate the differences in fetuin-A between normal condi-
tions and extra-osseous calcification stress.
RESULTS
Characterization of adenine rats
Prior to all subsequent examinations, we investigated the basal
characteristics of adenine-induced renal failure in rats. Male
Wistar rats were divided randomly into either the control or
adenine group at age 10 weeks. We fed CE-2 diet containing
0.75% adenine to adenine group rats for 5 weeks, whereas
control rats were provided normal CE-2 diet for 5 weeks. When
compared with control rats, serum urea nitrogen, creatinine,
magnesium, and inorganic phosphate increased significantly in
adenine rats (Table 1), although serum calcium and albumin
levels decreased in adenine rats (Table 1). The urinary volume
and water intake of adenine rats increased temporarily at 2
weeks into the adenine-feeding period (Tables 2 and 3).
Excretion of creatinine and minerals in urine decreased
significantly at 4 and 5 weeks into the adenine-feeding period
(Table 2). Adenine rats ate less food and lost body weight
(Table 3). Although marked increases in urea nitrogen and
inorganic phosphate and marked decreases in food intake and
body weight were observed, adenine rats shared similar
characteristics with human CKD patients.
Table 1 | Serum parameters of adenine rats
Adenine administration period
Parameters Control 2 weeks 4 weeks 5 weeks
Urea nitrogen (mg/100 ml) 20.16±2.60 91.66±18.12a 265.69±30.32a 332.58±52.26a
Creatinine (mg/100 ml) 0.62±0.08 1.11±0.26b 3.08±0.31a 3.36±0.54a
Albumin (g/100 ml) 4.11±0.21 3.75±0.10b 3.51±0.18a 3.24±0.32a
Calcium (mg/100 ml) 9.25±0.30 8.98±0.50 8.45±0.44b 7.46±0.70a
Magnesium (mg/100 ml) 2.48±0.14 3.71±0.24a 5.31±0.56a 5.29±0.46a
Inorganic phosphate (mg/100 ml) 7.26±0.21 7.49±1.72 18.53±1.53a 19.00±2.45a
Serum parameters of adenine rats are summarized. The serum samples of control group were collected at age 15 weeks.
All results are presented as means±s.d. (N=8 in each group: aPo0.001 vs control; bPo0.05).
Table 2 | Urinary parameters of adenine rats
Adenine administration period
Parameters 0 week 2 weeks 4 weeks 5 weeks
Urinary volume (ml/6 h)
Control 1.5±0.2 1.6±0.4 2.5±0.7 2.2±1.3
Adenine 1.4±0.3 6.6±2.3a 3.3±1.4 2.3±0.7
Adenine+alendronate 1.4±0.2 5.5±1.9a 2.6±1.6 2.4±0.6
Creatinine (mg/6 h)
Control 1.08±0.16 1.23±0.39 1.95±0.33 1.70±0.63
Adenine 1.16±0.19 0.94±0.24 0.32±0.16a 0.17±0.04a
Adenine+alendronate 1.10±0.13 0.85±0.26b 0.23±0.17a 0.19±0.04a
Calcium (mg/6 h)
Control 262.0±86.2 234.7±112.0 297.5±110.9 316.5±26.1
Adenine 235.5±75.3 69.6±29.6c 75.9±36.7a 77.9±20.1c
Adenine+alendronate 217.3±84.1 82.9±73.4c 23.1±12.1a 24.4±6.3a
Magnesium (mg/6 h)
Control 583.7±127.7 564.3±274.1 947.4±244.0 681.0±359.1
Adenine 533.2±174.6 732.7±169.4 209.0±66.1a 192.3±52.2c
Adenine+alendronate 547.3±140.9 756.0±294.2 327.6±208.7c 221.6±61.2c
Phosphate (mg/6 h)
Control 1499.4±504.8 1727.8±839.3 2588.0±930.8 2357.3±1085.8
Adenine 1605.4±580.1 2053.6±662.9 1244.6±524.1c 907.6±292.3c
Adenine+alendronate 1502.3±417.3 1987.6±865.2 982.8±485.9a 767.1±205.6a
Urinary parameters of adenine rats are summarized. Urine was collected between 9:00 and 15:00 hours at the indicated time period.
All results are presented as means±s.d. (N=5–8 in each group: aPo0.001 vs control; bPo0.05; cPo0.01).
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In CKD patients, the prevalence of vascular calcification is
clearly higher than in the general population.22 Similar to the
extra-osseous calcification in CKD patients, adenine rats at 5
weeks had medial calcification in the aorta (Figure 1a).
Vascular calcification was localized to the media of the vessel
wall (Figure 1b). The mineral contents of the aorta in the
adenine group at 5 weeks were significantly higher when
compared with controls (Figure 1c and d).
Fetuin-A decreased in adenine rat liver and serum
As adenine rats share characteristics with CKD patients, we
examined fetuin-A expression levels in these rats. In
accordance with earlier reports, the predominant fetuin-
A-expressing organ was the liver in normal control rats
(Figure 2a).23–25 Adenine rats expressed less hepatic fetuin-A
at both the mRNA (Figure 2b) and protein levels (Figure 2c).
In CKD patients, low serum fetuin-A levels, but not low
hepatic fetuin-A levels, have been reported in association with
vascular calcification.10,12,13 To examine serum fetuin-A con-
centrations, we employed western blot analysis with TrueBlot
(eBioscience, San Diego, CA, USA) as a secondary antibody (see
Methods). Although the reduction rate was smaller than the
hepatic change, serum fetuin-A was also lower in adenine rats
(Figure 2d). We confirmed that no signal was detectable without
applying the anti-fetuin-A first antibody (Figure 2d). In Figure
2e and f, we quantified the signal intensities in Figure 2c and d,
respectively. Both the hepatic and serum fetuin-A reductions
were statistically significant.
In order to clarify the reasons why hepatic fetuin-A levels
decreased in adenine rats, we performed histological analysis
(Figure 3). Despite the drastic change in hepatic fetuin-A levels
(Figure 2b and c), there were no obvious histological
differences between normal (Figure 3a) and 5-week adenine
rat liver (Figure 3b), except for the lower glycogen deposits in
adenine rat liver. Serum asparate aminotrasferase (Figure 3c)
and alanine aminotrasferase (Figure 3d), in adenine rats, were
at comparable levels as in normal control rats. These data
indicate that the downregulation of fetuin-A was not because of
inflammatory changes or necrosis of the liver. Using the rat
liver cell line H4IIEC3 (kindly provided by Dr Tetsuo Takehara,
Department of Gastroenterology and Hepatology, Osaka
University Graduate School of Medicine, Osaka, Japan), we
also confirmed that adenine did not directly downregulate
fetuin-A (data not shown). Food restriction apparently
suppressed hepatic fetuin-A at both the mRNA (Figure 3e)
and protein levels (Figure 3f). As the food intake in adenine
rats was significantly lower than in normal rats (Table 3),
deteriorated nutritional status could explain, at least partly, the
suppression of fetuin-A in adenine rat liver.
Neither hepatic nor serum fetuin-A levels were associated
with vascular calcification in adenine rats
In order to examine whether low hepatic and/or serum
fetuin-A levels were correlated with the extent of extra-
osseous calcification, we inhibited ectopic calcification in
Table 3 | Physical parameters of adenine rats
Adenine administration period
Parameters 0 week 2 weeks 4 weeks 5 weeks
Food intake (g/day)
Control 21.4±2.2 21.1±1.7 19.7±1.5 20.1±2.3
Adenine 21.5±2.0 5.1±1.4a 4.6±0.76a 2.7±1.4a
Adenine+
alendronate
21.6±1.6 6.1±2.2a 3.7±1.4a 3.8±1.2a
Water intake (ml/day)
Control 23.9±2.5 23.4±3.4 23.7±2.9 26.3±4.3
Adenine 23.5±2.9 42.5±6.7a 27.8±3.0b 17.0±8.5
Adenine+
alendronate
22.6±2.3 40.3±7.6a 29.2±5.6b 23.6±6.7
Body weight (g)
Control 242.8±9.5 283.3±5.2 313.6±4.8 320.7±9.3
Adenine 245.3±11.7 174.2±9.0a 144.0±9.4a 117.5±7.6a
Adenine+
alendronate
248.6±13.5 181.4±12.5a 150.2±11.0a 128.0±2.7a
Physical parameters of adenine rats are summarized.
All results are presented as means±s.d. (N=5–8 in each group: aPo0.001 vs control;
bPo0.05).
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Figure 1 | Extra-osseous calcification in adenine rats. Extra-
osseous calcification in adenine rats is shown. von Kossa staining
revealed ectopic calcification in adenine rats. Ascending aortas in
normal rats (a) and 5-week adenine rats (b) were analyzed.
Calcification of the aorta was localized exclusively in the media of
the vessel wall (black area). Original magnification,  100.
(c) Macroscopically, Alizarin red staining showed arterial
calcification in 5-week adenine rats (red area). (d) Arteries from
5-week adenine rats contained significantly higher amounts of
calcium (Ca), magnesium (Mg), and inorganic phosphate (IP). All
results are presented as means±s.d. (N¼ 10 in each group:
*Po0.05; ***Po0.001 vs control).
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adenine rats by weekly alendronate injection. Calcification of
the aorta, as assessed by Alizarin red staining, disappeared
completely in alendronate-treated rats (Figure 4a). The aortic
mineral contents of alendronate-injected adenine rats almost
disappeared completely (Figure 4b). Vehicle- and alendro-
nate-injected 5-week adenine rats had similar levels of
hepatic fetuin-A mRNA (Figure 5a) and protein (Figure
5b). Serum fetuin-A was also at similar levels in these two
groups (Figure 5c). Quantification of Figure 5b and c
confirmed that alendronate treatment did not affect the
expression levels of hepatic (Figure 5d) or serum (Figure 5e)
fetuin-A. These findings indicate that hepatic and/or serum
fetuin-A levels are not always correlated with extra-osseous
calcification.
Fetuin-A was complexed with minerals in adenine rat serum,
but not in alendronate-injected rats
For the further characterization of fetuin-A under extra-
osseous calcification stress, we centrifuged and analyzed
serum samples. Centrifugation of adenine rat serum, but not
normal serum, gave a small pellet at the bottom of each tube.
The precipitate contained two major proteins around 63 and
13 kDa (Figure 6a, black arrow and white arrow, respectively)
on SDS-PAGE. To rule out the possibility that the 63-kDa
protein was contaminating serum protein albumin, we
performed SDS-PAGE analysis using both pellet and serum
samples (Figure 6b). The major band in a 4-week adenine rat
serum (Figure 6b, lane 4, gray arrow) was albumin, as
confirmed by mass spectrometry (data not shown). However,
the 63-kDa band of this pellet (Figure 6b, lane 2, black arrow)
showed a markedly different migration pattern from
albumin. The sample in Figure 6b, lane 3, is the 4-week
adenine pellet without 150 mM NaCl wash (see Methods). In
this lane, we observed albumin (gray arrow) and other non-
specific pellet-associated contaminants, in addition to the 63-
kDa protein (black arrow). These results indicate that the 63-
kDa protein is not albumin. We obtained similar results using
5-week adenine samples (Figure 6b, lanes 5–7).
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Figure 2 | Hepatic and serum fetuin-A concentrations in adenine rats. (a) The predominant fetuin-A-expressing organ was the liver.
RT–PCR products from normal rat tissue samples were applied to 2% agarose gels and stained with ethidium bromide. With induction of
renal failure by adenine, uremic rats expressed less hepatic fetuin-A at both the mRNA (b) and protein levels (c). (N¼ 6 in real-time PCR and
N¼ 4 in western blot analysis: ***Po0.001 vs control). (d) Serum fetuin-A was also reduced in adenine rats. Without applying anti-fetuin-A
antibody [1st Ab ()], no signals were detectable. Using Image J software, the signal intensities of (c and d) were quantified in (e and f),
respectively. The reductions in hepatic fetuin-A (e) and serum fetuin-A (f) levels were statistically significant. All results are presented as
means±s.d. (N¼ 4 in each group: **Po0.01; ***Po0.001 vs control).
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We centrifuged the serum samples of Figure 5 in the same
manner (Figure 6c). Although vehicle-treated adenine rat
serum showed the same results as Figure 6a (Figure 6c, lanes
2–5), the 63-kDa band disappeared in alendronate-injected
adenine rat serum (Figure 6c, lanes 6–9). Even at higher
centrifugation speeds, the 63-kDa band was not seen (Figure
6c, lanes 10–13).
We excised the 63-kDa band from the Coomassie Brilliant
Blue-stained polyacrylamide gels, performed trypsinization,
and then conducted matrix-assisted laser desorption/ioniza-
tion time of flight mass spectrometry. Figure 7a shows the
obtained spectrum. Interrogation of the peptide mass
fingerprint identified the protein as fetuin-A. The matched
peptides are listed in Table 4. As the sequence coverage was
only 24%, MS/MS analysis was utilized in order to validate
the amino-acid sequence matched in peptide mass finger-
print. MS/MS analysis revealed the highest peak in peptide
mass fingerprint, which is indicated by the red ellipse in
Figure 7a, to be VGQPGDAGAAGPVAPLCPGR (Figure 7b).
The combined analysis of peptide mass fingerprint and
MS/MS by Mascot search confirmed the 63-kDa protein to be
fetuin-A, with a significantly high probability score of 133.
The 13-kDa bands (Figure 6a, white arrow) were a mixture of
hemoglobin subunit b-1 and subunit a-1/2 with a probability
score of 141 (Table 5).
We quantified the amounts of calcium, magnesium, and
inorganic phosphate contained in the pellet. Four- and five-
week adenine rat pellets contained significantly elevated levels
of these minerals (Figure 8a). The serum samples in Figure 5
were also analyzed. Vehicle-injected adenine rat pellets had
comparable levels of each mineral (Figure 8b). However,
alendronate-injected adenine rat serum pellets contained very
low levels of each mineral (Figure 8b). Ethylenediamine-
tetraacetic acid (EDTA) addition to adenine rat serum prior to
centrifugation in vitro eliminated completely the 63-kDa band,
but had no effect on the 13-kDa bands (Figure 8c, lanes 4, 5,
12, and 13). These data indicate that the precipitated fetuin-A
comprised a fetuin–mineral complex (FMC), and that a
divalent cation is required to form the FMC. We also
examined whether higher-speed centrifugation would sedi-
ment more FMC, but the amounts were comparable with
those obtained with 16,000g centrifugation (63-kDa bands in
Figure 8c, lanes 6, 7, 14, and 15). To confirm that
centrifugation at 16,000g was sufficient to sediment all FMC
in adenine rat serum, we centrifuged the supernatant samples
obtained in Figure 8c, lanes 2, 3, 10, and 11 at 125,000g
(Figure 8c, lanes 8, 9, 16, and 17). Centrifugation at 125,000g
did not yield any additional 63-kDa protein (Figure 8c, lanes 8,
9, 16, and 17). Thus, centrifugation at 16,000g was sufficient to
sediment all FMC. The pellets containing hemoglobin
consistently had a small red component at the bottom (data
not shown). The fact that the addition of EDTA did not affect
sedimentary hemoglobin (Figure 8c, 13-kDa bands) indicates
that these samples had some erythrocyte contamination.
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deposits in adenine rats. No inflammatory cells were observed.
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hepatic fetuin-A at both the mRNA (e) and protein levels (f).
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restriction (5 g/day) for 1 week. All results are presented as
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We investigated the mechanisms behind the alendronate
inhibition of FMC formation in adenine rats. The serum
parameters are listed in Table 6. Although serum creatinine
was decreased slightly in alendronate-treated adenine rats,
both vehicle- and alendronate-injected adenine rats had
severe renal dysfunction and similar elevated levels of serum
magnesium and phosphate (Table 6). Reflecting the low
serum calcium levels (Table 6), alendronate-treated adenine
rats excreted less urinary calcium (Table 2). Food intake and
body weight loss were comparable between vehicle- and
alendronate-treated adenine rats (Table 3). As bisphospho-
nates are pyrophosphate analogs, we then examined whether
alendronate directly dissociates FMC (Figure 9a). Using
adenine 5-week serum samples, we assessed the direct effects
of alendronate on FMC in the same manner as in Figure 8c,
lanes 12 and 13. Unlike EDTA, alendronate addition to
adenine rat serum prior to centrifugation in vitro did not
affect FMC sedimentation (Figure 9a). Another possible
mechanism was its effect on bone metabolism. As earlier
studies have indicated, bone resorption correlates with
vascular calcification.26–28 Adenine rats had strongly elevated
levels of serum intact parathyroid hormone (PTH) (Figure
9b) and C-terminal telopeptides of type I collagen (Figure
9c). Alendronate repressed bone resorption (Figure 9c) and
fixed calcium in the bone. A resultant decrease in serum
calcium levels (Table 6) and an elevation of intact PTH levels
were also observed (Figure 9b). As calcium supply was
indispensable for FMC formation (Figure 10c and d), the
disrupted FMC formation by alendronate is apparently the
result of fixing calcium in the bone.
All of these data on FMC, in adenine rat serum, show that
the physical characteristics of serum fetuin-A are different
between normal and adenine rats. The appearance of FMC,
but not hepatic or serum fetuin-A concentrations, was
correlated with extra-osseous calcification.
Fetuin–mineral complex contributes to the inhibition of
spontaneous mineral precipitation
For further functional analysis of FMC, we reconstituted
FMC in vitro. Tris-buffered saline (TBS, pH 7.4) (Figure 10a)
or TBS-dialyzed serum (Figure 10b–e) was incubated with the
indicated concentrations of mineral mixtures at 37 1C for 3 h
and was centrifuged for 3 s at 1890g (Figure 10a and b) or for
2 h at 16,000g (Figure 10c–e). We analyzed the phosphate
levels in the pellet (Figure 10a–c) and the constituent proteins
of the pellet (Figure 10d and e). After mineral mixture
incubation in TBS, we observed spontaneous precipitation of
mineral salts in some tubes. To collect the precipitate
attached at the wall of experimental tube, we centrifuged
each tube for 3 s at 1890g. In the absence of calcium, the
mixture of magnesium and phosphate did not yield any
precipitation (Figure 10a, mixture 1). Maximum mineral
precipitation was obtained from a mixture of calcium and
phosphate without magnesium (Figure 10a, mixture 8).
Magnesium decreased spontaneous mineral precipitation in a
dose-dependent manner (Figure 10a, mixtures 8–14), whereas
calcium increased mineral precipitation (Figure 10a, mixtures
1–7). TBS-dialyzed serum inhibited completely the sponta-
neous mineral precipitation (Figure 10b). This inhibition was
accompanied by FMC formation (Figure 10c and d). In the
absence of magnesium, elevation of calcium and phosphate
by 10 mM each resulted in the highest amount of FMC with
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Figure 5 | Effects of alendronate on hepatic and serum fetuin-A.
Alendronate had no effect on hepatic and serum fetuin-A levels of
5-week adenine rats. Samples isolated from liver or serum (control
rats, 5-week adenine rats with weekly vehicle or alendronate
injection) were analyzed. When compared with control rats,
adenine rats showed reduced hepatic fetuin-A at both the mRNA
(a) and protein levels (b) (N¼ 6 in real-time PCR and N¼ 4 in
western blot analysis: ***Po0.001 vs control). However,
alendronate changed neither mRNA (a) nor protein levels
(b) of hepatic fetuin-A in 5-week adenine rats. (c) Serum fetuin-A
from vehicle- or alendronate-treated 5-week adenine rats was also
comparable. The signal intensities of (b and c) were quantified in
(d and e), respectively. Five-week adenine rats had less hepatic
and serum fetuin-A than normal control rats. However, there were
no significant differences between vehicle- and alendronate-
treated 5-week adenine rats. All results are presented as
means±s.d. (N¼ 4 in each group: **Po0.01; ***Po0.001
vs control).
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numerous additional proteins (Figure 10d and e and Table
S1). Concomitant addition of magnesium suppressed the
amount of fetuin-A in the pellet and vanished the other
components (Figure 10d). The resultant pellet protein
composition with magnesium was essentially identical to
those found in adenine rats. These data indicated that the
amounts of FMC were correlated with the risk of sponta-
neous mineral precipitation.
Fetuin-A in the fetuin–mineral complex was fully
phosphorylated
The characteristics of fetuin-A in the FMC were different
from those of serum fetuin-A. We examined the phos-
phorylation status of fetuin-A using Phos-tag acrylamide
gel (NARD Institute, Hyogo, Japan). The acrylamide-pendant
Phos-tag ligand provides phosphate affinity SDS-PAGE for
mobility shift detection of phosphorylated proteins.29 Using
this agent, we found that serum fetuin-A had at least three
different phosphorylated forms (Figure 11a, black and gray
arrows), in addition to non-phosphorylated fetuin-A (Figure
11a, white arrow). Serum from adenine rats also had three
different phosphorylated fetuin-A isoforms (Figure 11a).
Fetuin-A in the FMC was essentially phosphorylated fully
(Figure 11b, black arrow). Partly or non-phosphorylated
fetuin-A (Figure 11b, gray and white arrows) did not
participate in FMC formation.
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Figure 6 | Fetuin-A precipitation in adenine rat serum, but not in alendronate-injected adenine rat serum. The physical characteristics
of fetuin-A in adenine rat serum were quite different from those in normal rats. (a) Two major proteins around 63 (black arrow) and 13 kDa
(white arrow) were precipitated by centrifugation in adenine rat serum. One hundred microliters of serum from each rat was processed as
described in Methods. The constituent proteins were visualized by SDS-PAGE followed by Coomassie Brilliant Blue staining. Lane 1,
molecular mass marker; Lanes 2–5, control rats; adenine rats at 2 weeks in Lanes 6–9, at 4 weeks in Lanes 10–13, and at 5 weeks in Lanes
14–17. (b) The 63-kDa band was different from serum protein albumin. Lane 1, molecular mass marker; Lane 2, pellet form 4-week adenine
serum with 150 mM NaCl wash (see Methods); Lane 3, pellet from 4-week adenine serum without 150 mM NaCl wash; Lane 4, 4-week adenine
serum. The same analysis as for Lanes 2–4 was performed using 5-week adenine serum in Lanes 5–7. Black and gray arrows indicate the 63-
kDa band and albumin, respectively. (c) The 63-kDa band disappeared in alendronate-injected adenine rat serum pellets. Centrifugation at
higher speed (125,000g) also failed to precipitate the 63-kDa protein.
Kidney International (2009) 75, 915–928 921
I Matsui et al.: Fetuin-A under calcification stress o r i g i n a l a r t i c l e
DISCUSSION
In this study, we examined the behavior of fetuin-A using rats
with adenine-induced renal failure. Based on our results,
fetuin-A markedly changes its characteristics under extra-
osseous calcification stress.
We showed that both hepatic and serum fetuin-A levels
were reduced in adenine rats. The difference in serum fetuin-A
between normal and adenine rats was smaller than that in
hepatic fetuin-A (Figure 2). Our results on rat serum fetuin-
A levels were similar to human data. According to a report by
Ketteler et al., serum fetuin-A levels, in healthy humans and
hemodialysis patients, are 0.72±0.19 and 0.66±0.28 g/l,
respectively.10 Both human and rat serum fetuin-A are
reduced in renal failure, but the difference is relatively small.
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Figure 7 | Mass spectrometry of 63-kDa protein. (a) The tryptic peptide mass fingerprint of 63-kDa migrating protein is shown.
Interrogation of this peptide mass fingerprint (PMF) identified the protein as rat fetuin-A. (b) Using the ion indicated in the red ellipse in
(a) as a precursor, MS/MS analysis confirmed the amino-acid sequence to be VGQPGDAGAAGPVAPLCPGR. Combined analysis by PMF and
MS/MS by Mascot search confirmed the 63-kDa protein to be rat fetuin-A with a significantly high probability score of 133.
Table 4 | Theoretical and measured masses of 63-kDa protein
Measured mass Calculated mass Residues Peptide sequence
869.51 869.49 51–57 (K)HLLQGFR(Q)
1846.02 1845.92 327–346 (K)VGQPGDAGAAGPVAPLCPGR(V)
1996.02 1995.91 104–120 (R)QQAEHAVEGDCDFHILK(Q)
2135.17 2135.06 306–326 (R)HAFSPVASVESASGEVLHSPK(V)
2514.31 2514.19 29–50 (R)ELACDDPETEHVALIAVDYLNK(H)
The peptides for the 63-kDa protein are listed. These peptides were matched for rat fetuin-A.
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In addition to the slightly reduced concentrations, serum
fetuin-A distinctively changed its characteristics in adenine
rats. We found that adenine rat serum contained FMC
(Figures 6–8). The characteristics of FMC in rat serum were
first described by Price et al.30–32 They discovered a high
molecular weight complex of calcium, phosphate, fetuin-A,
and matrix Gla protein in the serum of etidronate-treated
rats.33 FMC is also known as calciprotein particles, in analogy
to lipoprotein particles.34,35 According to a recent report by
Heiss et al., FMC develop in vitro in a two-step process.34,35
They suggested that fetuin-A buffers mineral ion super-
saturation by stabilizing precursors of mineralization as
colloids, i.e., primary FMC. Subsequently, the primary FMC
underwent a transformation process to form secondary FMC,
which resulted from a highly anisotropic crystalline needle
outgrowth of primary FMC. Fetuin-A was indispensable for
primary FMC formation. Many other acidic proteins,
including albumin, ovalbumin, and prothrombin, enhanced
greatly the fetuin-A-triggered formation of secondary
FMC.34,35 In this study, the constituent protein of FMC in
adenine rats was solely fetuin-A (Figure 6). Based on the
protein composition, FMC in adenine rat serum appears to
be primary FMC. Similar to the report by Heiss et al., we
found some contribution by acidic proteins to FMC under
artificial conditions (Figure 10d and e). The additional
constituents, thrombospondin-1, a-1-macroglobulin, pro-
thrombin, albumin, and apo E, were all acidic serum proteins
(Figure 10e). Thus, the FMC in Figure 10d, lane 8 seems to
correspond with the secondary FMC. However, it is
important to note that the secondary FMC was found only
under artificial conditions, and magnesium eliminated the
acidic proteins from FMC (Figure 10d). In the report by
Heiss et al., they examined the transformation of FMC from
the primary form to the secondary form in TBS containing
calcium, phosphate, and proteins of interest without
magnesium.35 They also presented a case of dialysis-
associated calcifying peritonitis with secondary FMC in
dialysate, but typical dialysate contains very low levels of
magnesium.35 Based on these observations, further studies
must be performed in order to elucidate whether secondary
FMC actually exists in vivo.
We confirmed that the appearance of FMC coincided with
vascular calcification and that hepatic or serum fetuin-A
concentrations were not correlated with the extent of vascular
calcification. In addition to this study on adenine-induced
renal failure rats, we found similar FMC in the serum of
subtotally nephrectomized rats, but the prevalence was
relatively low (data not shown). The uselessness of measuring
serum or hepatic fetuin-A levels as a marker for extra-osseous
calcification stress was verified by studies on fetuin-A null mice,
as fetuin-A null mice with mixed C57BL/6-129/Sv or with
C57BL/6 genetic background were phenotypically normal on
standard diet.9,36 However, it is also true that fetuin-A is an
important inhibitor of extra-osseous calcification under certain
conditions. In the fetuin-A null mice, ectopic micro-calcifica-
tion of soft tissue was observed in only a limited number of
female ex-breeders.9,36 A pregnancy-associated phenomenon,
known as physiological maternal hyperparathyroidism, in-
creased the calcium load in circulation and generated micro-
calcification. In addition, these fetuin-A null mice, including
male mice, developed severe calcification of various organs on a
mineral- and vitamin D-rich diet.9 Moreover, virtually all
fetuin-A null mice with DBA/2 genetic background, which is an
inbred strain prone to calcification, particularly in the heart,
developed severe calcification of various organs on standard
diet, although this severe calcification phenotype was never
Table 5 | Theoretical and measured masses of 13-kDa protein
Measured mass Calculated mass Residues Peptide sequence
911.44 911.47 2–9 (M)VHLTDAEK(A)a
914.46 914.50 10–18 (K)AAVNGLWGK(V)a
1012.50 1012.51 33–41 (R)MFAAFPTTK(T)b
1086.61 1086.62 92–100 (K)LRVDPVNFK(F)b
1119.55 1119.55 9–17 (K)TNIKNCWGK(I)b
1125.55 1125.56 97–105 (K)LHVDPENFR(L)a
1251.71 1251.71 129–140 (K)FLASVSTVLTSK(Y)b
1273.73 1273.72 32–41 (R)LLVVYPWTQR(Y)a
1297.64 1297.63 19–31 (K)VNPDDVGGEALGR(L)a
1396.66 1396.64 122–133 (K)EFTPCAQAAFQK(V)a
1421.79 1421.78 134–147 (K)VVAGVASALAHKYH(-)a
1571.74 1571.73 18–32 (K)IGGHGGEYGEEALQR(M)b
1713.02 1713.01 106–121 (R)LLGNMIVIVLGHHLGK(E)a
1734.86 1734.86 42–57 (K)TYFSHIDVSPGSAQVK(A)b
2005.90 2005.91 42–60 (R)YFDSFGDLSSASAIMGNPK(V)a
2021.90 2021.90 42–60 (R)YFDSFGDLSSASAIMGNPK(V)+Oxidation(M)a
2234.06 2234.09 78–96 (K)HLDNLKGTFAHLSELHCDK(L)a
2296.11 2296.14 70–91 (K)AADHVEDLPGALSTLSDLHAHK(L)b
2565.30 2565.33 70–93 (K)AADHVEDLPGALSTLSDLHAHKLR(V)b
3174.54 3174.52 101–128 (K)FLSHCLLVTLACHHPGDFTPAMHASLDK(F)b
The peptides for the 13-kDa protein are listed. These peptides were matched for rat hemoglobin subunit a-1/2 and subunit b-1.
aMatched peptides for hemoglobin subunit b-1.
bMatched peptides for hemoglobin subunit a-1/2.
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observed in DBA/2 wild mice.9 All of these observations suggest
that fetuin-A exerts its anti-calcification effects only under
extra-osseous calcification stress by organizing water-soluble
FMC, but it may not be an important effector under normal
conditions. As shown in Figure 10, unwanted mineral
precipitation was inhibited by FMC. Ectopic calcifications in
fetuin-A null mice under extra-osseous calcification stress can
be explained by the failure of FMC formation. This notion is in
accordance with our in vivo results, as we found FMC only in
adenine rats, and did not observe FMC in normal rats. In this
context, serum FMC levels seem to reflect extra-osseous
calcification stress.
Alendronate completely inhibited vascular calcification in
adenine rats (Figure 4). This inhibition was accompanied by
the disappearance of FMC (Figure 6c). These results indicate
that the extra-osseous calcification stress was blocked by
alendronate. Extra-osseous calcification stress could be
induced from two mineral supply pathways, calcium and
phosphate load from food intake and minerals derived from
bone. Under our experimental conditions, the main source of
extra-osseous calcification stress was apparently bone, as
adenine rats ate less food (Table 3), and their bone turnover
was elevated significantly (Figure 9b and c). Unlike EDTA
(Figure 8c), alendronate had no direct effect on FMC (Figure
9a). Although calcification inhibition by alendronate may
have been derived from its pyrophosphate-like effects in aorta
in situ, our experimental data indicated that alendronate
inhibited FMC formation (Figure 6c) and vascular calcifica-
tion (Figure 4) by blocking the mineral supply from bone
(Figure 9a and Table 6). These results also suggest that the
origin of FMC, at least under our experimental conditions,
was bone.
The addition of EDTA to adenine rat serum prior to
centrifugation inhibited completely the precipitation of FMC,
indicating that a divalent cation is required to form FMC
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Figure 8 | Characterization of fetuin–mineral complex. Precipitated fetuin-A was complexed with minerals. (a) Pellets from 4- and 5-week
adenine serum contained significantly elevated levels of calcium (Ca), magnesium (Mg), and inorganic phosphate (IP). Serum was processed
in the same way as for Figure 6, and the resultant pellet was dissolved in 150 mM HCl. Each mineral was quantified colorimetrically. (N¼ 8 in
each group: ***Po0.001 vs control) (b) Ca, Mg, and IP contents in the pellet fraction were diminished by alendronate injection. (N¼ 8 in
each group: **Po0.01; ***Po0.001) (c) Addition of EDTA prior to centrifugation eliminated the 63-kDa band. EDTA was added to serum
samples in vitro just before centrifugation. Lane 1, molecular mass marker; Lanes 2 and 3, 16,000g pellets from 4-week adenine serum
without EDTA; Lanes 4 and 5, 16,000g pellets with 50 mM EDTA. Pellet size did not differ significantly between centrifugation at 16,000g
(Lanes 2 and 3) and at 125,000g (Lanes 6 and 7). Further centrifugation of the 16,000g sample supernatant at 125,000g did not result in any
sedimentation (Lanes 8 and 9). Similar results were obtained with 5-week adenine serum (Lanes 10–17).
Table 6 | Serum parameters of alendronate-injected adenine
rats
Adenine administration
for 5 weeks
Parameters +vehicle +alendronate
Urea nitrogen (mg/100 ml) 324.57±68.25 303.59±70.71
Creatinine (mg/100 ml) 3.75±0.67 2.77±0.36a
Albumin (g/100 ml) 3.56±0.09 3.21±0.24a
Calcium (mg/100 ml) 7.95±1.44 5.00±0.64b
Magnesium (mg/100 ml) 5.72±0.44 5.01±0.59
Inorganic phosphate (mg/100 ml) 19.15±2.32 16.02±4.24
Serum parameters of vehicle-injected or alendronate-injected adenine 5-week rats
are summarized.
All results are presented as means±s.d. (N=5 in each group: aPo0.05; bPo0.01).
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(Figure 8c). In vitro analysis revealed that increasing amounts
of calcium contributed to larger amounts of FMC in the
presence of phosphate, but this was not the case with
magnesium (Figure 10c and d). Magnesium is reported to be
a potent inhibitor of calcification. Hypomagnesemia results
in ectopic calcification, and dietary supplementation with
magnesium reduces medial calcification in the aorta in
animal experimental models.37,38 Low serum magnesium is
also correlated with increased arterial calcification in human
dialysis patients.39,40 The effects of magnesium on FMC and
vascular calcification appear to be because of the nature of
magnesium itself. Mg2þ ions substitute readily for Ca2þ in
the apatite crystal lattice and cause crystal poisoning.41 Our
experiments also showed that magnesium reduces the
spontaneous precipitation of minerals in a dose-dependent
manner (Figure 10a, lanes 8–14). As a consequence,
magnesium reduced FMC (Figure 10c and d). These results
also support our conclusion that serum FMC is a marker of
extra-osseous calcification. Although serum calcium
phosphate products have been discussed in terms of
pathophysiological relevance to increased extra-osseous
calcification stress,42 spontaneous mineral precipitation
varied in the presence of magnesium under constant
concentrations of calcium and phosphate (Figure 10a). Thus,
FMC, but not calcium phosphate products, more precisely
reflected calcification stress (Figure 10).
Serum fetuin-A has at least three differentially phosphory-
lated forms (Figure 11). We confirmed that the fetuin-A in
FMC was phosphorylated fully. These results show clearly
that only a specific sub-population of serum fetuin-A acts as
FMC. Several other researchers have reported that physiolo-
gically active fetuin-A must be phosphorylated, except for
fetuin-A in bone. Only phosphorylated fetuin-A inhibits
insulin-receptor tyrosine kinase and modulates hepatocyte
growth factor signaling.43,44 These results also support the
notion that it is useless to quantify total serum fetuin-A
without centrifugation.
In conclusion, the amount of FMC, but not hepatic or
serum fetuin-A levels, apparently reflects extra-osseous
calcification stress in rats. Our results suggest that the
measurement of FMC, rather than serum total fetuin-A, is
required for assessment of extra-osseous calcification stress.
METHODS
Animals
Eight-week-old male Wistar rats were purchased from Japan SLC
Inc. (Hamamatsu, Japan). Rats were handled in a humane manner
in accordance with the guidelines of the Animal Committee of
Osaka University. Rats were fed the normal CE-2 diet containing
1.05% calcium, 0.35% magnesium, and 1.06% phosphorus (Nihon
Clea Inc., Tokyo, Japan) at the animal facility of Osaka University
School of Medicine. At age 10 weeks, animals were divided
randomly into the control and adenine groups. For the control
group, the standard CE-2 diet was continued for another 5 weeks.
For the adenine group, CE-2 diet containing 0.75% adenine (Wako,
Osaka, Japan) was given for 5 weeks.45 To determine the effects of
alendronate, renal failure was induced by adenine, as described
above, and alendronate dissolved in phosphate buffered saline (PBS)
(pH 7.4) was administrated subcutaneously at a dose of 700mg/kg
body weight once a week from age 10 to 14 weeks. The final
administration of alendronate was 1 week prior to the kill. At the
indicated periods, rats were anesthetized by intraperitoneal admin-
istration of pentobarbital. During the kill, blood was allowed to clot
at room temperature, and serum was collected by centrifugation at
1400g, and was frozen at 80 1C until use.
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Figure 9 | Effects of alendronate on fetuin–mineral complex (FMC). (a) Addition of alendronate to 5-week adenine rat serum in vitro had
no effect on FMC. Alendronate was added to 5-week adenine serum samples in vitro just before centrifugation, and the resultant pellets
were assessed in the same way as for Figure 6a. Lane 1, molecular mass marker; Lane 2, 5-week adenine rat serum without alendronate.
Alendronate was added to 5-week adenine serum to increase levels by 50 mg/ml (Lane 3), 100 mg/ml (Lane 4), 250 mg/ml (Lane 5), 500 mg/ml
(Lane 6), or 1000 mg/ml (Lane7). Pellets contained comparable levels of fetuin-A. Alendronate did not directly dissociate FMC. (b) Serum
intact PTH levels and (c) serum C-terminal telopeptides of type I collagen levels were analyzed. Five-week adenine rats with vehicle injection
had significantly elevated levels of serum intact PTH and C-terminal telopeptides of type I collagen. Alendronate suppressed serum C-
terminal telopeptides of type I collagen.
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Western blot analysis
Isolated tissues were lysed in cell lysis buffer (Cell Signaling
Technology, Danvers, MA, USA). Each sample was subjected to
SDS-polyacrylamide gel electrophoresis using 10–20% Super Sep gel
(Wako, Osako, Japan), and was electroblotted onto a Hybond-P
membrane (GE Healthcare, Waukesha, WI, USA). The membrane
was incubated in anti-fetuin-A antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or in anti-b-actin antibody (Sigma, St Louis,
MO, USA). To visualize the signals, Goat TrueBlot HRP
(eBioscience, San Diego, CA, USA) as an anti-fetuin-A antibody,
or HRP-conjugated anti-mouse IgG antibody (Dako, Denmark) as
an anti-b-actin antibody was used in combination with Super Signal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).
On preliminary examination, western blot analysis of serum fetuin-
A with HRP-conjugated secondary antibody resulted in a strong
broad signal at B55 kDa because of interference from immuno-
globulins derived from model rat serum samples. To avoid this
cross-reaction, we used TrueBlot as a secondary antibody, as this
antibody detects preferentially the native disulfide form of IgG and
eliminates interference by reduced immunoglobulins. To analyze the
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(a and b) or for 2 h at 16,000g (c–e). Phosphate levels in the pellet (a–c) or constituent protein of the pellet (d and e) were examined. All
mixtures contained 10 mM phosphate. Lane M, molecular mass marker. In Lanes 1–7 and Lanes 8–14, each sample contained 10 mM
magnesium or 10 mM calcium, respectively. Calcium levels (Lanes 2–7) or magnesium levels (Lanes 9–14) were increased by 0.25 mM (Lanes 2
and 9), 0.50 mM (Lanes 3 and 10), 1.0 mM (Lanes 4 and 11), 2.5 mM (Lanes 5 and 12), 5.0 mM (Lanes 6 and 13), or 10 mM (Lanes 7 and 14). After
the mixture was incubated at 37 1C, mineral salts precipitated spontaneously in TBS (a). The precipitate attached at the walls of an Eppendolf
tube was collected by centrifugation for 3 s at 1890g. In the presence of TBS dialyzed serum, spontaneous precipitation of minerals was inhibited
completely (b). This inhibition was accompanied by FMC formation (b–d). Elevation of calcium and phosphate levels by 10 mM each without
magnesium resulted in the highest amount of FMC formation with numerous additional proteins (d, Lane 8). The additional composition of
sedimentary protein was examined by laser desorption/ionization time of flight mass spectrometry (e). Matched peptides are listed in Table S1. All
results are presented as means±s.d. (N¼ 5 in each group: *Po0.05; **Po0.01; ***Po0.001 vs mixture No.8).
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phosphorylation status of fetuin-A, Phos-tag SDS-PAGE was
performed using 8% polyacrylamide gel containing 100 mM Mn2þ -
Phos-tag according to the manufacturer’s instructions (NARD
Institute, Hyogo, Japan).
Quantitative reverse transcription-PCR
RNA was extracted from each tissue with TRIZOL (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
To quantify the expression of mRNA, real-time SYBR-Green PCR
analysis was performed. The primer sets had the following
sequences: fetuin-A forward, 50-ccagtgtcattccacaccaga-30; fetuin-A
reverse, 50-cgcagctatcacaaactcca-30; b-actin forward, 50-agccatgtacgt
agccatcc-30; b-actin reverse, 50-ctctcagctgtggtggtgaa-30.
Evaluation of fetuin–mineral complex in serum of adenine rats
For measurement of the serum levels of FMC, serum was processed
as described previously, with slight modification.32,33,46 Briefly,
100-ml aliquots of serum in 1.5-ml tubes were centrifuged for 2 h at
room temperature at 16,000g or 125,000g. After discarding the
supernatant, each tube was rinsed with 200 ml of 150 mM NaCl
solution and re-centrifuged for 5 min at 16,000g. The resultant
pellets were dissolved in 50 ml of 150 mM HCl for calcium,
magnesium, and inorganic phosphate analysis. For the Coomassie
Brilliant Blue stain, pellets were dissolved in 80 ml of Laemmli
buffer containing 60 mM EDTA and 15-ml aliquots were loaded
onto the 10–20% Super-Sep polyacrylamide gel (Wako, Osako,
Japan).
Formation of fetuin–mineral complex in vitro
Serum obtained from normal 15-week-old Wistar rats was
dialyzed against 20 mM TBS(pH 7.4). The formation of FMC in
vitro was performed, as described previously, with slight modifica-
tion.32,33,46 Briefly, to increase the concentrations of calcium,
magnesium, and phosphate, 0.4 M CaCl2 and/or 0.4 M MgCl2 was
added to a serum aliquot in order to achieve twice the desired final
level of added calcium and magnesium, and an aliquot of 0.4 M
sodium phosphate (pH 7.4) was added to a second serum aliquot in
order to achieve twice the desired final level of added phosphate. Fifty
microliters of calcium- and/or magnesium-boosted serum aliquot was
then expelled rapidly into 50ml of phosphate-boosted serum in a 1.5-
ml tube. The modified serum was mixed and incubated at 37 1C for
3 h, and was centrifuged. The resultant pellet was processed as
described above.
Protein identification by matrix-assisted laser desorption/
ionization mass spectrometry
Gel pieces containing proteins of interest were excised and subjected
to in-gel digestion with sequencing-grade-modified trypsin (Pro-
mega, Madison, WI, USA). ZipTip C18 (Millipore, Inc., Schwalbach,
Germany)-concentrated tryptic digested samples were prepared by
co-crystallization of a saturated solution of the matrix (a-cyano-4-
hydroxycinnamic acid in 50:50 (vol/wt%) acetonitrile/0.1% tri-
fluoroacetic acid in water). Mass spectra were recorded on a Bruker
Ultraflex TOF/TOF (Bruker Daltonics, Inc., Bremen, Germany) in
positive ion reflectron mode. Tryptic monoisotopic peptide masses
were searched against NCBI and SwissProt databases using the
Mascot (Matrix Science, Ltd, London, UK) program.
Biochemical parameters
Serum and urinary biochemical parameters, urea nitrogen,
creatinine, albumin, calcium, magnesium, and inorganic phosphate
were measured by clinical diagnostic reagents (Wako, Osaka, Japan).
To determine the mineral contents of FMC, pellets from control and
adenine rat serum were dissolved in 150 mM HCl and ana-
lyzed.32,33,46 To investigate mineral accumulation in the aorta, the
appropriate alizarin red-stained tissues were minced and freeze
dried. After weighing the dried aorta, each sample was extracted
with 150 mM HCl overnight at room temperature in order to
dissolve the minerals. Intact PTH and C-terminal telopeptides of
type I collagen were measured by Rat BioActive Intact PTH ELISA
Kit (Immutopics, Inc., San Clemente, CA, USA) and RatLaps ELISA
(Nordic Bioscience, Herlev, Denmark), respectively.
Statistical analysis
Statistical significance among multiple experimental values was
evaluated using Dunnett’s test, and the difference between two
experimental values was assessed by a non-paired t-test. Statistical
significance was defined as Po0.05. All results are presented as
means±s.d.
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Figure 11 | Characterization of fetuin-A involved in
fetuin–mineral complex (FMC). Fetuin-A in the FMC was
phosphorylated fully . Using Phos-tagacrylamide gel, we analyzed
the phosphorylation status of fetuin-A. (a) Normal rat serum had
phosphorylated (black arrow), partially phosphorylated (gray
arrows) and non-phosphorylated (white arrow) fetuin-A (Lanes 1
and 2). Four-week (Lanes 3 and 4) and 5-week (Lanes 5 and 6)
adenine serum also had these forms. Alkaline phosphatase
treatment of each serum sample verified the fastest migrating
bands (white arrow) to be the non-phosphorylated form (Lanes
7–12). (b) Fully phosphorylated fetuin-A was present in the FMC.
As a migration marker, normal rat serum was applied in Lane 1.
Fetuin-A in the FMC in 4-week (Lanes 2 and 3) and 5-week (Lanes
4 and 5) adenine rats exhibited the slowest migration. Alkaline
phosphatase treatment verified the phosphorylation of fetuin-A in
the FMC (Lanes 6–9).
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SUPPLEMENTARY MATERIAL
The matched peptides for each protein identified in Figure 10e are
listed in Table S1
Table S1. Theoretical and measured masses of precipitate proteins.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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